STUART MILAN: Open Payments
NPI 1689766958 · FLOWOOD, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$919 in 41 payments from 9 companies in 2025. Trend: 2023 $473 · 2024 $453 · 2025 $919
Food & beverage: $919
| Company | Payments | Amount |
|---|---|---|
| Axsome Therapeutics, Inc. | 6 | $227 |
| ABBVIE INC. | 14 | $213 |
| Vanda Pharmaceuticals Inc. | 8 | $202 |
| Otsuka America Pharmaceutical, Inc. | 5 | $106 |
| Indivior Inc. | 3 | $70 |
| Janssen Pharmaceuticals, Inc | 2 | $42 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $25 |
| Braeburn Inc. | 1 | $18 |
| Supernus Pharmaceuticals, Inc. | 1 | $15 |
Products named: Auvelity, VRAYLAR, FANAPT, REXULTI, SUBLOCADE, SPRAVATO, CAPLYTA, BRIXADI.
Industry payments across MS — which companies pay providers there.
